TLRY
Tilray Brands, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$3.03
−0.33%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 963.1M | 915.5M | 821.3M | 1.1B | 844.7M |
| Cost of Revenue | 688.8M | 655.0M | 580.7M | 770.7M | 646.8M |
| Gross Profit | 274.3M | 260.4M | 240.6M | 304.3M | 198.0M |
| Operating Expenses | |||||
| R&D Expense | 409.0K | 361.0K | 284.0K | 865.2K | 918.6K |
| SG&A Expense | 318.1M | 295.2M | 260.4M | 341.6M | 311.1M |
| General & Admin Expense | 220.2M | 203.6M | 167.3M | 233.8M | 222.5M |
| Selling & Marketing Expense | 97.9M | 91.6M | 93.1M | 107.9M | 88.6M |
| Other Expenses | 33.0M | 27.9M | 2.3B | 199.9M | 1.7B |
| Total Operating Expenses | 351.5M | 323.5M | 2.5B | 542.4M | 2.0B |
| Cost and Expenses | 1.0B | 978.5M | 3.1B | 1.3B | 2.7B |
| Operating Income (EBIT) | (77.2M) | (63.0M) | (2.3B) | (238.1M) | (1.8B) |
| Non-Operating | |||||
| Interest Income | — | 6.2M | 11.4M | 17.5M | 44.5M |
| Interest Expense | 23.4M | 29.9M | 41.3M | 67.1M | 62.8M |
| Net Interest Income | (23.4M) | (23.7M) | (30.0M) | (49.6M) | (18.3M) |
| Other Non-Op Income/Expense | (48.4M) | (25.0M) | (19.7M) | (101.2M) | (108.4M) |
| Non-Operating Income (excl Interest) | 12.0M | (4.9M) | (21.7M) | 34.1M | 45.6M |
| EBT (Pre-Tax Income) | (125.6M) | (88.1M) | (2.3B) | (339.3M) | (2.0B) |
| Income Tax Expense | 21.1M | 17.1M | (121.0M) | (36.3M) | (9.7M) |
| Bottom Line | |||||
| Net Income | (164.2M) | (122.6M) | (2.2B) | (333.8M) | (2.0B) |
| Earnings from Cont. Ops | (146.7M) | (105.2M) | (2.2B) | (303.0M) | (1.9B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (164.2M) | (122.6M) | (2.2B) | (333.8M) | (2.0B) |
| Per Share | |||||
| Basic EPS | ($1.40) | ($1.09) | ($24.56) | ($4.50) | ($31.70) |
| Diluted EPS | ($1.40) | ($1.09) | ($24.56) | ($4.50) | ($31.70) |
| Revenue Per Share | $7.22 | $8.19 | $9.22 | $14.48 | $13.67 |
| Shares | |||||
| Basic Shares Outstanding | 133.3M | 111.8M | 89.0M | 74.3M | 61.8M |
| Diluted Shares Outstanding | 133.3M | 111.8M | 89.0M | 74.3M | 61.8M |
| Profitability Metrics | |||||
| EBITDA | (18.5M) | 9.5M | (2.1B) | (99.3M) | (1.7B) |
| D&A | 70.7M | 67.6M | 133.5M | 172.9M | 175.3M |
| EBIT | (89.2M) | (58.1M) | (2.3B) | (272.2M) | (1.9B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Aug 1, 2026